NATIONAL INSTITUTES OF HEALTH
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung
- Conditions
- Metastatic CancerBreast Cancer
- First Posted Date
- 2006-03-13
- Last Posted Date
- 2015-04-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1
- Registration Number
- NCT00301730
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain
- First Posted Date
- 2006-03-13
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 44
- Registration Number
- NCT00301847
- Locations
- 🇺🇸
Ingalls Cancer Care Center at Ingalls Memorial Hospital, Harvey, Illinois, United States
🇺🇸Central Illinois Hematology Oncology Center, Springfield, Illinois, United States
🇺🇸Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States
The Family Investigation of Nephropathy and Diabetes Study
- Conditions
- DiabetesDiabetic Nephropathy
- First Posted Date
- 2006-03-10
- Last Posted Date
- 2020-04-28
- Target Recruit Count
- 9031
- Registration Number
- NCT00301249
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma
- Conditions
- Sarcoma
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00295984
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
A Randomized, Double-Blinded, Placebo-Controlled Trial of Corticosteroid Therapy Following Portoenterostomy
- Conditions
- Biliary Atresia
- Interventions
- Drug: PlaceboDrug: Corticosteroids
- First Posted Date
- 2006-02-22
- Last Posted Date
- 2019-10-22
- Target Recruit Count
- 141
- Registration Number
- NCT00294684
- Locations
- 🇺🇸
Texas Children's Hospital/Baylor College of Medicine, Houston, Texas, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital and Regional Medical Center, Seattle, Washington, United States
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
- Conditions
- Anaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueIntraocular LymphomaNodal Marginal Zone B-cell LymphomaPrimary Central Nervous System Hodgkin LymphomaPrimary Central Nervous System Non-Hodgkin LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell Lymphoma
- Interventions
- First Posted Date
- 2006-02-17
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00293345
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Clinical Approaches to Ileal Pouch Dysfunction
- Conditions
- Pouchitis
- First Posted Date
- 2006-02-17
- Last Posted Date
- 2010-03-18
- Target Recruit Count
- 64
- Registration Number
- NCT00293553
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Conditions
- B-cell Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic Leukemia
- Interventions
- Biological: bevacizumab
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT00290810
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
- Conditions
- B-cell Chronic Lymphocytic LeukemiaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueRecurrent Marginal Zone LymphomaMalignant NeoplasmNodal Marginal Zone B-cell LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Immunoblastic Large Cell Lymphoma
- Interventions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2014-05-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 89
- Registration Number
- NCT00290472
- Locations
- 🇺🇸
Decatur Memorial Hospital, Decatur, Illinois, United States
🇺🇸Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne, Indiana, United States
Genistein in Preventing Breast Cancer in Women at High Risk for Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 126
- Registration Number
- NCT00290758
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States